Australia's most trusted
source of pharma news
Friday, 12 December 2025
Posted 11 December 2025 AM
A Federal Court judge has moved to protect a major schizophrenia drug from early generic competition, placing an injunction on launching the new brand.
Johnson & Johnson has been successful in securing an interlocutory injunction against Arrotex subsidiary Juno to prevent it launching its generic versions of Invega Sustenna on the PBS, reported Lawyerly.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.